Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road

MM Levine, KL Kotloff, EM Barry, MF Pasetti… - Nature Reviews …, 2007 - nature.com
More than 50 years of research has yielded numerous Shigella vaccine candidates that
have exemplified both the promise of vaccine-induced prevention of shigellosis and the …

Shigella flexneri infection: pathogenesis and vaccine development

AV Jennison, NK Verma - FEMS microbiology reviews, 2004 - academic.oup.com
Shigella flexneri is a gram-negative bacterium which causes the most communicable of
bacterial dysenteries, shigellosis. Shigellosis causes 1.1 million deaths and over 164 million …

Shigella's ways of manipulating the host intestinal innate and adaptive immune system: a tool box for survival?

A Phalipon, PJ Sansonetti - Immunology and cell biology, 2007 - Wiley Online Library
Shigella, a Gram‐negative invasive enteropathogenic bacterium, causes the rupture,
invasion and inflammatory destruction of the human colonic epithelium. This complex and …

Abandon the mouse research ship? Not just yet!

MF Osuchowski, DG Remick, JA Lederer, CH Lang… - Shock, 2014 - journals.lww.com
Many preclinical studies in critical care medicine and related disciplines rely on hypothesis-
driven research in mice. The underlying premise posits that mice sufficiently emulate …

Progress and pitfalls in Shigella vaccine research

EM Barry, MF Pasetti, MB Sztein, A Fasano… - Nature reviews …, 2013 - nature.com
Renewed awareness of the substantial morbidity and mortality that Shigella infection causes
among young children in developing countries, combined with technological innovations in …

Broadly protective Shigella vaccine based on type III secretion apparatus proteins

FJ Martinez-Becerra, JM Kissmann… - Infection and …, 2012 - Am Soc Microbiol
Shigella spp. are food-and waterborne pathogens that cause severe diarrheal and
dysenteric disease associated with high morbidity and mortality. Individuals most often …

[HTML][HTML] Serum IgG antibodies to Shigella lipopolysaccharide antigens–a correlate of protection against shigellosis

D Cohen, S Meron-Sudai, A Bialik, V Asato… - Human vaccines & …, 2019 - Taylor & Francis
Shigella is a leading cause of diarrhea among children globally and of diarrheal deaths
among children under 5 years of age in low-and middle-income countries. To date, no …

Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose …

F Micoli, O Rossi, V Conti, O Launay, AS Sciré… - Frontiers in …, 2021 - frontiersin.org
Shigella is the second most deadly diarrheal disease among children under five years of
age, after rotavirus, with high morbidity and mortality in developing countries. Currently, no …

Functional and antigen-specific serum antibody levels as correlates of protection against shigellosis in a controlled human challenge study

AA Shimanovich, AD Buskirk, SJ Heine… - Clinical and Vaccine …, 2017 - Am Soc Microbiol
Shigella is an important cause of diarrheal disease in young children living in developing
countries. No approved vaccines are available, and the development of vaccine candidates …

[HTML][HTML] Development of Shigella conjugate vaccines targeting Shigella flexneri 2a and S. flexneri 3a using a simple platform-approach conjugation by squaric acid …

M Kelly, A Mandlik, RC Charles, S Verma… - Vaccine, 2023 - Elsevier
There is a need for vaccines effective against shigella infection in young children in resource-
limited areas. Protective immunity against shigella infection targets the O-specific …